Cell & Gene: The Podcast
Erin Harris
Cell & Gene, the most valuable online resource for delivering in-depth content from authoritative authors and sources to professionals in the CGT sector, introduces Cell & Gene: The Podcast. In each episode, Cell & Gene Chief Editor, Erin Harris, will talk to industry and academic leaders about their current initiatives and how they are moving the sector forward.
Episodes
Mentioned books
Mar 3, 2022 • 19min
Restoration of Immune Balance with Anish Suri, Ph.D., President and CSO at Cue Biopharma
We love to hear from our listeners. Send us a message.Cue Biopharma's Anish Suri, Ph.D., explains why the clinical-stage biopharma is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the body to transform the treatment of cancer.Subscribe to the podcast!Apple | Spotify | YouTube Visit my website: Cell & Gene Connect with me on LinkedIn
Feb 17, 2022 • 18min
REGENXBIO's Nina Hunter, Ph.D. Details the Accelerated Approval Pathway for Gene Therapies
We love to hear from our listeners. Send us a message.REGENXBIO's VP of Regulatory and Science Policy, Nina Hunter, Ph.D., shares potential solutions to gene therapies' regulatory roadblocks and why the accelerated approval pathway is so pertinent. Subscribe to the podcast!Apple | Spotify | YouTube Visit my website: Cell & Gene Connect with me on LinkedIn
Feb 3, 2022 • 21min
Selecta Biosciences' Dr. Carsten Brunn on Gene Therapy with AAV Vectors
We love to hear from our listeners. Send us a message.Selecta Biosciences' President and CEO Dr. Carsten Brunn details the company's ImmTOR platform, which can mitigate unwanted immune responses that cause immune-related toxicities that impose significant treatment challenges with current therapies.Subscribe to the podcast!Apple | Spotify | YouTube Visit my website: Cell & Gene Connect with me on LinkedIn
Jan 20, 2022 • 33min
Cellevolve Bio's Dr. Derrell Porter on the Need for Diversity and Inclusion in Biotech
We love to hear from our listeners. Send us a message.Cellevolve Bio's founder and CEO. Dr. Derrell Porter shares his experience with starting up a cell therapy company and why we, as an industry, need to advocate for more Black leaders and leaders of color in the biotech industry.Subscribe to the podcast!Apple | Spotify | YouTube Visit my website: Cell & Gene Connect with me on LinkedIn
Jan 6, 2022 • 20min
RNA's Advantages Over Other Cell Therapies with Cartesian's CSO
We love to hear from our listeners. Send us a message.Dr. Michael Singer, CSO at Cartesian Therapeutics, details why RNA has advantages over other cell therapies, the company's three RNA trials, and the therapeutic benefit of multiple modifications.Subscribe to the podcast!Apple | Spotify | YouTube Visit my website: Cell & Gene Connect with me on LinkedIn
Dec 22, 2021 • 19min
Vor Biopharma's CEO on Genome Engineering of Hematopoietic Stem Cells
We love to hear from our listeners. Send us a message.Vor Biopharma's CEO Dr. Robert Ang explains the company's lead engineered hematopoietic cell (eHSC) product candidate, genome engineering of HSCs, and the cell manufacturing process needed to leverage genome engineering technologies for the cells they're creating.Subscribe to the podcast!Apple | Spotify | YouTube Visit my website: Cell & Gene Connect with me on LinkedIn
Dec 9, 2021 • 28min
AVROBIO on Patient Advocacy's Role in Clinical Trial Development & Recruitment
We love to hear from our listeners. Send us a message.Fernanda Copeland, Global Head, Patient Advocacy & Engagement at AVROBIO, explains how to incorporate community education, patient feedback, and more to improve clinical trial development and recruitment.Subscribe to the podcast!Apple | Spotify | YouTube Visit my website: Cell & Gene Connect with me on LinkedIn
Nov 24, 2021 • 19min
Understanding CAR-M Technology with Carisma Therapeutics' Dr. Debora Barton
We love to hear from our listeners. Send us a message.Carisma Therapeutics’ Dr. Barton breaks down the latest in CAR-M technology as well as the company's Phase 1 First-in-Human Study of Adenovirally Transduced Anti-HER2 CAR Macrophages in Subjects with HER2 Overexpressing Solid Tumors.Subscribe to the podcast!Apple | Spotify | YouTube Visit my website: Cell & Gene Connect with me on LinkedIn
Nov 11, 2021 • 15min
Inside the Gene Therapy for Coronary Artery Disease with XyloCor Therapeutics' Albert Gianchetti
We love to hear from our listeners. Send us a message.XyloCor Therapeutics' EXACT clinical trial is a Phase 1/2 multicenter, open-label, single arm, dose escalation trial for coronary artery disease — the most common type of heart disease — with gene therapy at its center.Subscribe to the podcast!Apple | Spotify | YouTube Visit my website: Cell & Gene Connect with me on LinkedIn
Oct 28, 2021 • 25min
Advancing Patient Engagement with Novartis Gene Therapies' Dr. Amy Nicole Nayar
Dr. Amy Nicole Nayar discusses patient engagement in cell and gene therapy, focusing on its impact on therapy development, trial enrollment, and cost reduction. She explores leveraging patient insights for shaping company strategies, educating about gene therapies, and advocating for access to innovative therapies. The podcast also delves into the motivation behind gene therapy innovation and the guest's collaborative spirit within the field.
